Nanotools for the delivery of antimicrobial peptides

Current Drug Targets

Volumn 13, Issue 9, 2012, Pages 1158-1172

  Urbán, Patricia ^a,b,c   Valle Delgado, Juan José ^a,b,c   Moles, Ernest ^a,b,c   Marques, Joana ^a,b,c   Díez, Cinta ^a,b,c   Fernàndez Busquets, Xavier ^a,b,c  

^a INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antibodies; Aptamers; Dendrimers; Liposomes; Nanomedicine; Nanoparticles; Nanovectors; Targeting

Indexed keywords

ANTIBODY; APTAMER; CARBOHYDRATE; CARBON NANOTUBE; CELL PENETRATING PEPTIDE; DNA; DRUG CARRIER; LIPOSOME; NANOPARTICLE; POLYMER; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; CELL TYPE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HUMAN; IMMUNOGENICITY; LIVER CELL CARCINOMA; MALARIA FALCIPARUM; NANOANALYSIS; NANOENCAPSULATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; NUCLEIC ACID STRUCTURE; PLASMODIUM FALCIPARUM; QUANTITATIVE ANALYSIS; REVIEW; STAPHYLOCOCCUS INFECTION;

ANTI-INFECTIVE AGENTS; DRUG DELIVERY SYSTEMS; NANOTECHNOLOGY; PEPTIDES;

EID: 84864538606     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802002302     Document Type: Review

References (200)

1. Brown KL, Mookherjee N, Hancock REW. Antimicrobial, host defence peptides and proteins. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, Ltd. 2007. DOI: 10.1002/9780470015902.a0001212.pub2.
2. Boix E. Eosinophil cationic protein. Methods Enzymol 2001; 341: 287-305.
3. Torrent M, Navarro S, Moussaoui M, Nogués MV, Boix E. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 2008; 47(11): 3544-55.
4. Waters LS, Taverne J, Tai PC, Spry CJ, Targett GA, Playfair JH. Killing of Plasmodium falciparum by eosinophil secretory products. Infect Immun 1987; 55(4): 877-81.
5. Adu B, Dodoo D, Adukpo S, et al. Polymorphisms in the RNASE3 gene are associated with susceptibility to cerebral malaria in Ghanaian children. PLoS One 2011; 6(12): e29465.
6. Venge P, Byström J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999; 29(9): 1172-86.
7. Torrent M, Cuyás E, Carreras E, et al. Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 2007; 46(3): 720-33.
8. Torrent M, Sánchez D, Buzón V, Nogués MV, Cladera J, Boix E. Comparison of the membrane interaction mechanism of two antimicrobial RNases: RNase 3/ECP and RNase 7. Biochim Biophys Acta 2009; 1788(5): 1116-25.
9. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41(7): 1413-22.
10. Couvreur P, Puisieux F. Nano-and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev 2005; 10(2-3): 141-62.
11. Pattani AS, Mandawgade SD, Patravale VB. Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of Polymyxin B. J Nanosci Nanotechnol 2006; 6(9-10): 2986-990.
12. Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm 2010; 76(1): 1-9.
13. Luppi B, Bigucci F, Cerchiara T, Mandrioli R, Di Pietra AM, Zecchi V. New environmental sensitive system for colon-specific delivery of peptidic drugs. Int J Pharm 2008; 358(1-2): 44-9.
14. Hamidi M, Zarrin A, Foroozesh M. Novel delivery systems for interferons. Crit Rev Biotechnol 2007; 27(3): 111-27.
15. Xiong XY, Li YP, Li ZL, et al. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release 2007; 120(1-2): 11-7.
16. Saltzman M, Desai T. Drug delivery in the BME curricula. Ann Biomed Eng 2006; 34(2): 270-75.
17. Orive G, Hernández RM, Rodríguez Gascón A, Domínguez-Gil A, Pedraz JL. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 2003; 14(6): 659-64.
18. Sershen S, West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2002; 54(9): 1225-35.
19. Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliv Rev 2002; 54(1): 53-77.
20. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41(6): 403-19.
21. Boudes P. Drug compliance in therapeutic trials: a review. Control Clin Trials 1998; 19(3): 257-68.
22. Tao SL, Desai TA. Microfabricated drug delivery systems: from particles to pores. Adv Drug Deliv Rev 2003; 55(3): 315-28.
23. Breimer DD. Future challenges for drug delivery. J Control Release 1999; 62(1-2): 3-6.
24. Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J Control Release 2003; 88(1): 117-26.
25. Davis SS, Illum L. Drug delivery systems for challenging molecules. Int J Pharm 1998; 176(1): 1-8.
26. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 2007; 18(3): 241-68.
27. Seale-Goldsmith MM, Leary JF. Nanobiosystems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1(5): 553-67.
28. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8(24): 1112-20.
29. Tan SY, Grimes S. Paul Ehrlich (1854-1915): man with the magic bullet. Singapore Med J 2010; 51(11): 842-3.
30. Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Nano Today 2005; 8(8): 18-26.
31. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res 2006; 23(1): 1-30.
32. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005; 57(15): 2106-29.
33. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3(9): 785-96.
34. Ishida O, Maruyama K, Sasaki K, Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm 1999; 190(1): 49-56.
35. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumorspecific nanoparticle delivery: effect of particle size. Cancer Res 2000; 60(16): 4440-5.
36. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002; 54(1): 135-47.
37. Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 1995; 17(1): 129-48.
38. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16(2-3): 195-214.
39. Katz E, Willner I. Integrated nanoparticle-biomolecule hybrid systems: synthesis, properties, and applications. Angew Chem Int Ed Engl 2004; 43(45): 6042-108.
40. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004; 64(21): 7668-72.
41. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008; 105(7): 2586-91.
42. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005; 21(19): 8852-7.
43. Urbán P, Estelrich J, Cortés A, Fernàndez-Busquets X. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. J Control Release 2011; 151(2): 202-11.
44. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55(3): 329-47.
45. Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 2006; 29(9): 1790-8.
46. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3(1): 16-20.
47. Bustami RT, Chan HK, Dehghani F, Foster NR. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res 2000; 17(11): 1360-6.
48. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett 1973; 36(3): 292-6.
49. Jasmine D, Tushar T. Role of liposomes in nanotechnology and drug delivery. Int J Drug Dev Res 2011; 3(1): 341-50.
50. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001; 1(6): 923-47.
51. Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol 2005; 391: 40-57.
52. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151(2): 201-15.
53. Storm G, Wilms HP, Crommelin DJ. Liposomes and biotherapeutics. Biotherapy 1991; 3(1): 25-42.
54. Kadir F, Zuidema J, Crommelin DJA. Liposomes as drug delivery systems for intramuscular and subcutaneous injections. In: Rolland A, Ed. Particulate Drug Carriers in Medical Applications. New York: Marcel Dekker 1993: 165-98.
55. ®liposomes: from theory to product. Adv Drug Deliv Rev 1997; 24(2-3): 165-77.
56. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1990; 1029(1): 91-7.
57. Kajiwara E, Kawano K, Hattori Y, Fukushima M, Hayashi K, Maitani Y. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy. J Control Release 2007; 120(1-2): 104-10.
58. Santos-Magalhaes NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010; 62(4-5): 560-75.
59. Singhal A, Gupta CM. Antibody-mediated targeting of liposomes to red cells in vivo. FEBS Lett 1986; 201(2): 321-26.
60. Shillcock JC, Lipowsky R. Tension-induced fusion of bilayer membranes and vesicles. Nat Mater 2005; 4(3): 225-8.
61. Wheeler JJ, Palmer L, Ossanlou M, et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 1999; 6(2): 271-81.
62. Nicolosi D, Scalia M, Nicolosi VM, Pignatello R. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int J Antimicrob Agents 2010; 35(6): 553-8.
63. Alipour M, Halwani M, Omri A, Suntres ZE. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 2008; 355(1-2): 293-8.
64. Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One 2009; 4(5): e5724.
65. Gregoriadis G. Liposomes as a drug delivery system: optimization studies. Adv Exp Med Biol 1988; 238: 151-9.
66. Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka LA. Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Deliv 2010; 7(12): 1387-98.
67. Sukhorukov GB, Rogach AL, Garstka M, et al. Multifunctionalized polymer microcapsules: novel tools for biological and pharmacological applications. Small 2007; 3(6): 944-55.
68. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70(1-2): 1-20.
69. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release 2004; 100(1): 5-28.
70. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2(5): 347-60.
71. Kavanagh OV, Earley B, Murray M, Foster CJ, Adair BM. Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-coglycolide) microspheres. Vaccine 2003; 21(27-30): 4472-80.
72. Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1(5): 463-74.
73. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999; 16(10): 1576-81.
74. Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009; 30(29): 5691-700.
75. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Expert Opin Drug Deliv 2005; 2(5): 843-54.
76. Lescure F, Seguin C, Breton P, Bourrinet P, Roy D, Couvreur P. Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles. Pharm Res 1994; 11(9): 1270-7.
77. Wikingsson L, Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 2002; 20(27-28): 3355-63.
78. Aynié I, Vauthier C, Chacun H, Fattal E, Couvreur P. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1999; 9(3): 301-12.
79. Bege N, Renette T, Jansch M, et al. Biodegradable poly(ethylene carbonate) nanoparticles as a promising drug delivery system with "stealth" potential. Macromol Biosci 2011; 11(7): 897-904.
80. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50(1): 27-46.
81. Peppas NA, Wood KM, Blanchette JO. Hydrogels for oral delivery of therapeutic proteins. Expert Opin Biol Ther 2004; 4(6): 881-7.
82. Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002; 7(10): 569-79.
83. Vinogradov SV. Colloidal microgels in drug delivery applications. Curr Pharm Des 2006; 12(36): 4703-12.
84. Patel VR, Amiji MM. Preparation and characterization of freezedried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Pharm Res 1996; 13(4): 588-93.
85. Li JK, Wang N, Wu XS. Poly(vinyl alcohol) nanoparticles prepared by freezing-thawing process for protein/peptide drug delivery. J Control Release 1998; 56(1-3): 117-26.
86. Salmaso S, Semenzato A, Bersani S, Matricardi P, Rossi F, Caliceti P. Cyclodextrin/PEG based hydrogels for multi-drug delivery. Int J Pharm 2007; 345(1-2): 42-50.
87. Gupta NV, Shivakumar HG. Preparation and characterization of superporous hydrogels as pH-sensitive drug delivery system for Pantoprazole sodium. Curr Drug Deliv 2009; 6(5): 505-10.
88. Gutowska A, Seok Bark J, Chan Kwon I, Han Bae Y, Cha Y, Wan Kim S. Squeezing hydrogels for controlled oral drug delivery. J Control Release 1997; 48(2-3): 141-8.
89. Tiwari AK, Gajbhiye V, Sharma R, Jain NK. Carrier mediated protein and peptide stabilization. Drug Deliv 2010; 17(8): 605-16.
90. Pattrick NG, Richardson SC, Casolaro M, Ferruti P, Duncan R. Poly(amidoamine)-mediated intracytoplasmic delivery of ricin Achain and gelonin. J Control Release 2001; 77(3): 225-32.
91. Wang H, Xu K, Liu L, et al. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials 2010; 31(10): 2874-81.
92. Schröder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 1996; 710(1-2): 121-4.
93. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47(1): 65-81.
94. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108(2-3): 193-214.
95. Al-Jamal KT, Ramaswamy C, Florence AT. Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev 2005; 57(15): 2238-70.
96. Marcos M, Martín-Rapún R, Omenat A, Serrano JL. Highly congested liquid crystal structures: dendrimers, dendrons, dendronized and hyperbranched polymers. Chem Soc Rev 2007; 36(12): 1889-901.
97. Liang C, Fréchet JMJ. Applying key concepts from nature: transition state stabilization, pre-concentration and cooperativity effects in dendritic biomimetics. Prog Polym Sci 2005; 30(3-4): 385-402.
98. Ihre HR, Padilla De Jesús OL, Szoka FC, Jr., Fréchet JM. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem 2002; 13(3): 443-52.
99. Padilla De Jesús OL, Ihre HR, Gagne L, Fréchet JM, Szoka FC Jr. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 2002; 13(3): 453-61.
100. Boas U, Heegaard PM. Dendrimers in drug research. Chem Soc Rev 2004; 33(1): 43-63.
101. Paleos CM, Tsiourvas D, Sideratou Z. Molecular engineering of dendritic polymers and their application as drug and gene delivery systems. Mol Pharm 2007; 4(2): 169-88.
102. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Preparation, cellular transport, and activity of polyamidoaminebased dendritic nanodevices with a high drug payload. Biomaterials 2006; 27(4): 660-9.
103. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR, Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 1996; 93(10): 4897-902.
104. Crespo L, Sanclimens G, Montaner B, et al. Peptide dendrimers based on polyproline helices. J Am Chem Soc 2002; 124(30): 8876-83.
105. Farrera-Sinfreu J, Giralt E, Castel S, Albericio F, Royo M. Cellpenetrating cis-gamma-amino-l-proline-derived peptides. J Am Chem Soc 2005; 127(26): 9459-68.
106. Wiwattanapatapee R, Carreño-Gómez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000; 17(8): 991-8.
107. Crespo L, Sanclimens G, Pons M, Giralt E, Royo M, Albericio F. Peptide and amide bond-containing dendrimers. Chem Rev 2005; 105(5):1663-81.
108. Agrawal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 2007; 28(22): 3349-59.
109. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005; 295(1-2): 221-33.
110. Lee JW, Ko YH, Park SH, Yamaguchi K, Kim K. Novel pseudorotaxane-terminated dendrimers: Supramolecular modification of dendrimer periphery. Angew Chem Int Ed 2001; 40(4): 746-9.
111. Mitchell JP, Roberts KD, Langley J, Koentgen F, Lambert JN. A direct method for the formation of peptide and carbohydrate dendrimers. Bioorg Med Chem Lett 1999; 9(19): 2785-8.
112. Chamorro C, Boerman MA, Arnusch CJ, Breukink E, Pieters RJ. Enhancing membrane disruption by targeting and multivalent presentation of antimicrobial peptides. Biochim Biophys Acta 2012 Apr 14. [Epub ahead of print].
113. Ciolkowski M, Petersen JF, Ficker M, et al. Surface modification of PAMAM dendrimer improves its biocompatibility. Nanomedicine 2012 Apr 26. [Epub ahead of print].
114. Calabretta MK, Kumar A, McDermott AM, Cai C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules 2007; 8(6): 1807-11.
115. Lopez AI, Reins RY, McDermott AM, Trautner BW, Cai C. Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. Mol Biosyst 2009; 5(10): 1148-56.
116. Wang B, Navath RS, Menjoge AR, et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int J Pharm 2010; 395(1-2): 298-308.
117. Wang AZ, Gu F, Zhang L, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008; 8(8): 1063-70.
118. Veiseh O, Sun C, Gunn J, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005; 5(6): 1003-8.
119. Durán JD, Arias JL, Gallardo V, Delgado AV. Magnetic colloids as drug vehicles. J Pharm Sci 2008; 97(8): 2948-83.
120. Xing Y, Smith AM, Agrawal A, Ruan G, Nie S. Molecular profiling of single cancer cells and clinical tissue specimens with semiconductor quantum dots. Int J Nanomedicine 2006; 1(4): 473-81.
121. Hosseinkhani H, Hosseinkhani M. Biodegradable polymer-metal complexes for gene and drug delivery. Curr Drug Saf 2009; 4(1): 79-83.
122. Ashley CE, Carnes EC, Phillips GK, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particlesupported lipid bilayers. Nat Mater 2011; 10(5): 389-97.
123. Soenen SJ, Hodenius M, De Cuyper M. Magnetoliposomes: versatile innovative nanocolloids for use in biotechnology and biomedicine. Nanomedicine (Lond) 2009; 4(2): 177-91.
124. Ghosh P, Yang X, Arvizo R, et al. Intracellular delivery of a membrane-impermeable enzyme in active form using functionalized gold nanoparticles. J Am Chem Soc 2010; 132(8): 2642-5.
125. Guerrero S, Araya E, Fiedler JL, et al. Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide. Nanomedicine (Lond) 2010; 5(6): 897-913.
126. Schaeublin NM, Braydich-Stolle LK, Schrand AM, et al. Surface charge of gold nanoparticles mediates mechanism of toxicity. Nanoscale 2011; 3(2): 410-20.
127. Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol Sci 2011; 120(suppl 1): S109-S129.
128. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005; 9(6): 674-9.
129. Sanz V, Coley H, Silva S, McFadden J. Modeling the binding of peptides on carbon nanotubes and their use as protein and DNA carriers. J Nanoparticle Res 2012; 14(2): 1-13.
130. Bandaru NM, Voelcker NH. Glycoconjugate-functionalized carbon nanotubes in biomedicine. J Mater Chem 2012; 22(18): 8748-58.
131. Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol 2011; 63(2): 141-63.
132. Pantarotto D, Briand JP, Prato M, Bianco A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun 2004; (1): 16-7.
133. Shi Kam NW, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J Am Chem Soc 2004; 126(22): 6850-1.
134. Heister E, Neves V, Lamprecht C, Silva SR, Coley HM, McFadden J. Drug loading, dispersion stability, and therapeutic efficacy in targeted drug delivery with carbon nanotubes. Carbon 2012; 50(2): 622-32.
135. Trzaskowski B, Jalbout AF, Adamowicz L. Molecular dynamics studies of protein-fragment models encapsulated into carbon nanotubes. Chem Phys Lett 2006; 430(1-3): 97-100.
136. Kümmerer K, Menz J, Schubert T, Thielemans W. Biodegradability of organic nanoparticles in the aqueous environment. Chemosphere 2011; 82(10): 1387-92.
137. Yang D, Campolongo MJ, Nhi Tran TN, Ruiz RC, Kahn JS, Luo D. Novel DNA materials and their applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2(6): 648-69.
138. Andersen ES, Dong M, Nielsen MM, et al. Self-assembly of a nanoscale DNA box with a controllable lid. Nature 2009; 459(7243): 73-6.
139. He Y, Ye T, Su M, et al. Hierarchical self-assembly of DNA into symmetric supramolecular polyhedra. Nature 2008; 452(7184): 198-201.
140. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5(4): 505-15.
141. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5(4): 496-504.
142. Geng Y, Discher DE. Hydrolytic degradation of poly(ethylene oxide)-block-polycaprolactone worm micelles. J Am Chem Soc 2005; 127(37): 12780-1.
143. Gao W, Chan JM, Farokhzad OC. pH-Responsive nanoparticles for drug delivery. Mol Pharm 2010; 7(6): 1913-20.
144. Sakthivel T, Toth I, Florence AT. Distribution of a lipidic 2.5 nm diameter dendrimer carrier after oral administration. Int J Pharm 1999; 183(1): 51-5.
145. Phua K, Leong KW. Microscale oral delivery devices incorporating nanoparticles. Nanomedicine (Lond) 2010; 5(2): 161-3.
146. Yamanaka YJ, Leong KW. Engineering strategies to enhance nanoparticle-mediated oral delivery. J Biomater Sci Polym Ed 2008; 19(12): 1549-70.
147. Lin YH, Mi FL, Chen CT, et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 2007; 8(1): 146-52.
148. Wong TW. Design of oral insulin delivery systems. J Drug Target 2010; 18(2): 79-92.
149. Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 2007; 117(2): 163-70.
150. Pan Y, Li YJ, Zhao HY, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249(1-2): 139-47.
151. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999; 35(2-3): 249-57.
152. Zola H. Monoclonal antibodies: Therapeutic uses. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, Ltd. 2011. DOI: 10.1038/npg.els.0004018.
153. Paul S, Planque S. Antibody engineering. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, Ltd. 2005. DOI: 10.1038/npg.els.0001278.
154. H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56(13): 3055-61.
155. Wu AM, Yazaki PJ. Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 2000; 44(3): 268-83.
156. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004; 64(8): 2853-7.
157. Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007; 25(8): 921-9.
158. Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem 1982; 257(1): 286-8.
159. Owais M, Varshney GC, Choudhury A, Chandra S, Gupta CM. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquineresistant Plasmodium berghei infections in mice. Antimicrob Agents Chemother 1995; 39(1): 180-4.
160. Vogel C-W. Preparation of immunoconjugates using antibody oligosaccharide moieties. In: Niemeyer CM, Ed. Methods in Molecular Biology. Totowa, NJ: Humana Press Inc., 2004: 87-108.
161. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007; 56(8): 2103-9.
162. Warren CL, Mohandas A, Chaturvedi I, Ansari AZ. Macromolecular interactions: aptamers. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, Ltd. 2009 DOI: 10.1002/ 9780470015902.a0003146.
163. O'Sullivan CK. Aptasensors-the future of biosensing? Anal Bioanal Chem 2002; 372(1): 44-8.
164. Abelson J. Directed evolution of nucleic acids by independent replication and selection. Science 1990; 249(4968): 488-9.
165. Collett JR, Cho EJ, Ellington AD. Production and processing of aptamer microarrays. Methods 2005; 37(1): 4-15.
166. Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003; 24(24): 4385-415.
167. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 2007; 24(11): 1977-92.
168. Futaki S. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharm 2002; 245(1-2): 1-7.
169. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008; 29(33): 4429-38.
170. Fernández-Carneado J, Kogan MJ, Pujals S, Giralt E. Amphipathic peptides and drug delivery. Biopolymers 2004; 76(2): 196-203.
171. Pujals S, Fernández-Carneado J, López-Iglesias C, Kogan MJ, Giralt E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta 2006; 1758(3): 264-79.
172. Pujals S, Sabidó E, Tarragó T, Giralt E. all-D proline-rich cellpenetrating peptides: a preliminary in vivo internalization study. Biochem Soc Trans 2007; 35(Pt 4): 794-6.
173. Chen L, Harrison SD. Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem Soc Trans 2007; 35(Pt 4): 821-5.
174. Law B, Quinti L, Choi Y, Weissleder R, Tung CH. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol Cancer Ther 2006; 5(8): 1944-9.
175. Dietz GP, Bähr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004; 27(2): 85-131.
176. Zhao M, Kircher MF, Josephson L, Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002; 13(4): 840-4.
177. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006; 281(6): 3544-51.
178. Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta 2004; 1665(1-2): 48-56.
179. Hashida H, Miyamoto M, Cho Y, et al. Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool. Br J Cancer 2004; 90(6): 1252-8.
180. Liu L, Xu K, Wang H, et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009; 4(7): 457-63.
181. Teixidó M, Giralt E. The role of peptides in blood-brain barrier nanotechnology. J Pept Sci 2008; 14(2): 163-73.
182. Fridkin M, Najjar VA. Tuftsin: its chemistry, biology, and clinical potential. Crit Rev Biochem Mol Biol 1989; 24(1): 1-40.
183. Agrawal AK, Gupta CM. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000; 41(2): 135-46.
184. Bucior I, Burger MM, Fernàndez-Busquets X. Carbohydratecarbohydrate interactions. In: Gabius H-J, Ed. The Sugar Code. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2009: 347-62.
185. Winterburn PJ, Phelps CF. The significance of glycosylated proteins. Nature 1972; 236(5343): 147-51.
186. Rüdiger H, Gabius H-J. The biochemical basis and coding capacity of the sugar code. In: Gabius H-J, Ed. The Sugar Code. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2009: 3-13.
187. Solís D, Romero A, Menéndez M, Jiménez-Barbero J. Proteincarbohydrate interactions: basic concepts and methods for analysis. In: Gabius H-J, Ed. The Sugar Code. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2009: 233-45.
188. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005; 4(12): 827-40.
189. Craig A, Scherf A. Molecules on the surface of the Plasmodium falciparum infected erythrocyte and their role in malaria pathogenesis and immune evasion. Mol Biochem Parasitol 2001; 115(2): 129-43.
190. Barragan A, Fernandez V, Chen Q, von Euler A, Wahlgren M, Spillmann D. The duffy-binding-like domain 1 of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding. Blood 2000; 95(11): 3594-9.
191. Vogt AM, Barragan A, Chen Q, Kironde F, Spillmann D, Wahlgren M. Heparan sulfate on endothelial cells mediates the binding of Plasmodium falciparum-infected erythrocytes via the DBL1tt domain of PfEMP1. Blood 2003; 101(6): 2405-11.
192. Gysin J, Pouvelle B, Le Tonqueze M, Edelman L, Boffa MC. Chondroitin sulfate of thrombomodulin is an adhesion receptor for Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol 1997; 88(1-2): 267-71.
193. Singh K, Gittis AG, Nguyen P, Gowda DC, Miller LH, Garboczi DN. Structure of the DBL3x domain of pregnancy-associated malaria protein VAR2CSA complexed with chondroitin sulfate A. Nat Struct Mol Biol 2008; 15(9): 932-8.
194. Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996; 272(5267): 1502-4.
195. Andrews KT, Klatt N, Adams Y, Mischnick P, Schwartz-Albiez R. Inhibition of chondroitin-4-sulfate-specific adhesion of Plasmodium falciparum-infected erythrocytes by sulfated polysaccharides. Infect Immun 2005; 73(7): 4288-94.
196. Ancsin JB, Kisilevsky R. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes. J Biol Chem 2004; 279(21): 21824-32.
197. Boyle MJ, Richards JS, Gilson PR, Chai W, Beeson JG. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood 2010; 115(22): 4559-68.
198. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006; 58(14): 1532-55.
199. Al-Jamal WT, Kostarelos K. Construction of nanoscale multicompartment liposomes for combinatory drug delivery. Int J Pharm 2007; 331(2): 182-5.
200. Al-Jamal WT, Kostarelos K. Liposome-nanoparticle hybrids for multimodal diagnostic and therapeutic applications. Nanomedicine (Lond) 2007; 2(1): 85-98.